CERE

Cerevel Therapeutics Holdings, Inc. (CERE) | Rumor.io

Cerevel Therapeutics Holdings

CERE

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about CERE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Nov 10

Cerevel Therapeutics' emraclidine treatment is highlighted for its potential benefits.
Cerevel Therapeutics Holdings, Inc. is mentioned as a company of interest in the context of pharmaceuticals and treatments.
There is no specific market-relevant information provided about the ticker CERE.

Generated by AI

Sentiment

Of the messages about CERE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	—
Bearish	—	—	—	—

Bullish· Nov 30

$CERE is in a strong accumulation phase and could pump at any moment.
$CERE has a good chance of reaching 10x in the next 3 months and is worth researching.
$CERE has a solid team behind it, including Binance Labs and several VCs, and an interesting marketing plan.

Bearish· Nov 8

The project has faced significant sell pressure due to private funding dumping, which may have contributed to its current bearish trend.
The company's poor campaign and management have led to a wasted high-potential project, with the asset experiencing negative sentiment and heavy sell-offs.
The asset's launch has been plagued by delays, which may have contributed to its current struggles, with some investors losing money and others describing it as "trash" and "fucked up".

Generated by AI

Topics

Of the messages about CERE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	0%
Announcements	—	—	100%	100%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0%

Dec 7

AbbVie to acquire Cerevel Therapeutics for $45.00 per share in cash, a total equity value of approximately $8.7 billion.
The acquisition is expected to be accretive to AbbVie's EPS in 2030.
The deal was announced on a day when Cerevel Therapeutics stock surged 12.9%, suggesting investors may have been aware of the acquisition before the official announcement.

Generated by AI

Community

Of the messages about CERE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	20%
Newcomers	0%	0%	0%	80%

Regulars· Oct 12

Cerevel Therapeutics Holdings, Inc. has announced the pricing of a $450 million public offering of common stock.
The public offering is a significant development for the company, which is seeking to raise capital through the sale of common stock.
The pricing of the public offering is a key event for investors, as it may impact the company's stock price and future prospects.

Newcomers· Dec 19

The Cerevel Therapeutics experimental schizophrenia drug's blood pressure study has cleared the deck ahead of pivotal readouts in 2024, with the company's stock price increasing by 25%.
The stock's near the high of the day, and a breakout could be expected with a float of 128.8M and a short float of 7.1%.
The stock's targets are set between $30.50-75 and $32.50-33, with support at $27.50-28.

Generated by AI

Also Discussed

Investors talking about CERE also mention

#	Name	Attention
1	XOMA CorporationXOMA	0%0
2	BioLife Solutions Inc.BLFS	0%0
3	Can-Fite BioPharma Ltd. ADRCANF	0%0
4	Element Solutions Inc.ESI	0%0
5	CTIC - CTI BioPharma Corp.	——
6	Vista Gold Corp.VGZ	0%new
7	AdvisorShares Focused Equity ETFCWS	0%0
8	Amplify Transformational Data Sharing ETFBLOK	0.02%new
9	SmartETFs Sustainable Energy II ETFSOLR	0%new
10	Equinox Gold Corp.EQX	0%new